Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression.

ABSTRACT:

Background

Infiltration into lymphatic vessels is a critical step in breast cancer metastasis. Lymphatics undergo changes that facilitate metastasis as a result of activation of the cells lining lymphatic vessels, lymphatic endothelial cells (LECs). Inhibition of activation by targeting VEGFR3 can reduce invasion toward lymphatics. To best benefit patients, this approach should be coupled with standard of care that slows tumor growth, such as chemotherapy. Little is known about how chemotherapies, like docetaxel, may influence lymphatics and conversely, how lymphatics can alter responses to therapy.

Methods

A novel 3D in vitro co-culture model of the human breast tumor microenvironment was employed to examine the contribution of LECs to tumor invasion and viability with doce

SUBMITTER: Harris AR 

PROVIDER: S-EPMC6034223 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature